# Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas

> **NCT02158975** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Lymphoma, T-Cell

## Interventions

- **DRUG:** MLN9708

## Key facts

- **NCT ID:** NCT02158975
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-10
- **Final completion:** 2016-11
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158975, "Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02158975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*